Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 12/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 12/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31285488 | 0.89 | KDM4E (0.56) | KDM4EALDH1A1HPGDPOLBGABRA2 | |
| SCHEMBL26092626 | 0.86 | KDM4E (0.59) | KDM4EALDH1A1HPGDPOLBGABRA2 | |
| SCHEMBL18189912 | 0.85 | KDM4E (0.58) | KDM4EALDH1A1HPGDPOLBGABRA2 | |
| SCHEMBL14605053 | 0.85 | ROCK1 (0.45) | KDM4EALDH1A1HPGDGABRA2GABRB2 | |
| SCHEMBL13764176 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1HPGDPOLBGABRA2 | |
| SCHEMBL31244472 | 0.83 | KDM4E (0.59) | KDM4EALDH1A1HPGDPOLBGABRA2 | |
| SCHEMBL19997306 | 0.82 | ROCK1 (0.43) | KDM4EALDH1A1HPGDPOLBROCK1 | |
| SCHEMBL13764178 | 0.82 | KDM4E (0.54) | KDM4EALDH1A1HPGDPOLBGABRA2 | |
| SCHEMBL18189892 | 0.82 | KDM4E (0.54) | KDM4EALDH1A1HPGDPOLBGABRA2 | |
| SCHEMBL31244541 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1HPGDPOLBGABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059680-A1 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2024-02-22 | — | — | US | disclosed |
| EP-4247809-A2 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | Elanco Tiergesundheit AG (CH) | 2023-09-27 | — | — | EP | disclosed |
| CN-116685584-A | N- (2, 3-dihydro-1, 4-benzoxazin-4-yl) -3-isopropyl-7- (2, 3, 5-trifluorophenyl) benzothiophene-2-carboxamide derivatives and similar compounds for the treatment of heartworm infections | 礼蓝动物保健有限公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022106469-A2 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106469-A2 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| CN-107567452-B | Imidazopiperazines and pyrazolopyrimidines and their use as AMPA receptor modulators | 詹森药业有限公司 | 2020-07-07 | — | — | CN | disclosed |
| US-10513523-B2 | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-24 | — | — | US | disclosed |
| EP-3288945-B1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-18 | — | — | EP | disclosed |
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| WO-2016176457-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016101119-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| US-8859543-B2 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-8859543-B2 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-8859543-B2 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| WO-2011110545-A1 | IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | PDE12, PDE10A, PDE5A | KDM4E 1959/4885ALDH1A1 315/4885HPGD 390/4885 |
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIK5, GRIN1, GRIN3A | KDM4E 3189/4885ALDH1A1 913/4885HPGD 901/4885 |
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | KDM4E 2571/4885ALDH1A1 3075/4885HPGD 940/4885 |
| US-20240059680-A1 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | TNNT2, TNNI3, SIRT5 | KDM4E 837/4885ALDH1A1 491/4885HPGD 650/4885 |
| US-10513523-B2 | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators | GRIK5, GRIN1, GRIN3A | KDM4E 3189/4885ALDH1A1 913/4885HPGD 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.